SS-31 Peptide Profile
SS-31, also known as Elamipretide, is a synthetic peptide designed to target and enhance mitochondrial function. As mitochondria are the energy powerhouses of cells, their optimal functioning is critical for overall health and aging. SS-31’s unique ability to protect and restore mitochondrial efficiency has made it a groundbreaking peptide in the fields of anti-aging, neuroprotection, and cardiology.
How It Works
SS-31 specifically targets cardiolipin, a phospholipid found in the inner mitochondrial membrane. Cardiolipin plays a key role in maintaining mitochondrial integrity and energy production. SS-31 binds to cardiolipin, protecting it from oxidative damage and stabilizing mitochondrial membranes. This action improves mitochondrial function, reduces the production of reactive oxygen species (ROS), and enhances cellular energy.
Key Benefits
Mitochondrial Protection
- Stabilizes mitochondrial membranes and reduces oxidative stress.
- Enhances ATP production, the energy currency of cells.
Anti-Aging Effects
- Slows cellular aging by protecting mitochondria from oxidative damage.
- Supports overall vitality and reduces age-related decline in energy levels.
Cardiovascular Health
- Protects heart muscle cells by improving mitochondrial efficiency.
- Reduces inflammation and damage associated with ischemia-reperfusion injury (e.g., heart attacks).
Neuroprotection
- Protects neurons from oxidative stress, reducing the risk of neurodegenerative diseases.
- Enhances cognitive function and slows progression of conditions like Alzheimer’s and Parkinson’s disease.
Muscle Health
- Improves endurance and recovery by enhancing mitochondrial function in muscle cells.
- Reduces muscle fatigue and weakness in conditions like sarcopenia and mitochondrial myopathy.
Applications
SS-31 is being explored for its therapeutic potential in the following areas:
- Cardiovascular Health: Treating heart failure, ischemia-reperfusion injury, and cardiomyopathies.
- Neurodegenerative Diseases: Protecting against Alzheimer’s, Parkinson’s, and other neurological disorders.
- Muscle Disorders: Addressing mitochondrial myopathies, muscle fatigue, and age-related muscle decline.
- Anti-Aging Therapies: Enhancing energy, vitality, and overall mitochondrial health to combat aging.
Dosage and Administration
SS-31 is typically administered via subcutaneous injection. The dosage varies depending on the specific condition and individual needs. Clinical trials and medical supervision are recommended to optimize its benefits.
Potential Side Effects
SS-31 has shown a favorable safety profile in clinical studies. Mild and rare side effects may include:
- Temporary injection site irritation.
- Fatigue or mild headache in some cases.
Current Research and Future Prospects
SS-31 is currently being studied in clinical trials for various conditions, including mitochondrial diseases, heart failure, and neurodegenerative disorders. Its ability to target the root cause of mitochondrial dysfunction positions it as a promising therapy for a wide range of age-related and chronic conditions.
Conclusion
SS-31 is a groundbreaking peptide with the potential to revolutionize treatments for mitochondrial dysfunction and age-related diseases. By enhancing mitochondrial efficiency, reducing oxidative stress, and improving cellular energy, SS-31 offers hope for better cardiovascular health, neuroprotection, and overall vitality. As research advances, SS-31 is poised to become a cornerstone in mitochondrial medicine and anti-aging therapies.
SS-31 Peptide Profile
THIS SS-31 (ELAMIPRETIDE) PEPTIDE INFORMATION IS FOR BOTH ADULT MALES AND ADULT FEMALES.
| Peptide / Product: SS-31 (Elamipretide) | Category / Goal | Example Medical- / Trial-Style Dose Range* | Route | Frequency Pattern* | Typical Course Length* | Notes |
|---|---|---|---|---|---|---|
| Adult Males – Clinical / Trial Context | Mitochondria-targeted peptide investigated for cardiomyopathy, heart failure, eye disease, and other mitochondrial disorders | Human trials have generally used weight-based dosing, commonly in the range of roughly 0.05–0.25 mg/kg per day, depending on indication and protocol. Some studies used fixed doses (for example tens of mg per day) in infusion or subcutaneous form, always decided by the research team or prescribing physician. | Intravenous infusion or subcutaneous injection, depending on the specific study or formulation. | In trials, dosing is often once daily, sometimes as a continuous IV infusion for a defined period (for example hours per day), or as a daily subcutaneous injection. Exact timing and schedule are written into the trial protocol, not chosen by the patient. | Course lengths in research have ranged from days (acute settings like cardiac surgery) up to several months (chronic heart failure or eye disease studies). Repeat or long-term use is determined by trial design and safety data, not by user preference. | For adult men, dosing is always tied to bodyweight, organ function, and specific disease. There is no approved “performance” or “wellness” dose for healthy users. All numbers must come from a doctor or research protocol, not the internet. |
| Adult Females – Clinical / Trial Context | Same core goal: improve mitochondrial function in specific diseases, NOT a general anti-aging or fat-loss shot | Women in trials receive the same mg/kg ranges as men, adjusted only for bodyweight, kidney function, and individual safety considerations. Fragile or older female patients may start at the low end of the protocol dose range or have slower titration. | IV or subQ, identical technical routes to male patients. | Frequency is also once daily or per protocol, sometimes with hospital-based infusions, sometimes with at-home subQ injections supervised by a clinical team. | Duration mirrors male protocols: short courses around surgical events, or weeks to months for chronic conditions, with frequent safety checks. | Females may have additional monitoring around bone density, anemia, or comorbid autoimmune or endocrine disease depending on the underlying mitochondrial problem. But again: dose is set by the protocol, not by DIY experimentation. |
| Both Sexes – How It’s Actually Used (Context Only) | Real-world pattern in research | SS-31 / elamipretide has been studied for conditions like Barth syndrome, heart failure with reduced ejection fraction, ischemia-reperfusion injury, and certain eye diseases. In all of these, it’s delivered as a prescription investigational drug, not a spa IV. | Route is chosen by the study: IV drip in hospital / outpatient infusion center, or daily home subQ injections with training. | Frequency is consistent, usually once daily, because the drug’s half-life and mitochondrial uptake dictate that pattern. | Courses are pre-specified: for example, 28 days, 12 weeks, 36 weeks, etc., and cannot be arbitrarily extended without safety data. | Outside true clinical trials or tightly supervised compassionate-use programs, using “SS-31” vials from gray-market sellers is basically gambling that what’s in the bottle is real, correctly dosed, and sterile — which often isn’t the case. |
| Both Sexes – “Anti-Aging / Performance” Marketing vs Reality | Misuse risk | On forums and some marketing sites, SS-31 is often pitched as a general mitochondrial, anti-aging, or athletic performance peptide. These uses are not standard, not FDA-approved, and not backed by large, high-quality human trials in healthy individuals. | DIY protocols you see online (for example fixed mg per day for “energy” or “recovery”) are not standardized and often ignore key issues like kidney function, drug interactions, or long-term safety. | Self-experimentation can hide developing side effects until they’re serious (e.g., kidney stress, blood-pressure changes, unexpected interactions with heart meds). | If someone is attracted to SS-31 solely for “longevity” or “gym performance,” that’s a sign to talk to a real physician about safer, better-studied strategies instead. | |
| Both Sexes – Monitoring & Safety in Proper Use | What clinicians watch | In trials, patients are monitored with vital signs, ECGs, blood and urine tests (kidney/liver markers, electrolytes), and disease-specific imaging or functional tests. Any new chest pain, rhythm change, or lab abnormality can lead to dose adjustment or discontinuation. | Infusion patients are supervised during and after the drip; subQ users get regular follow-up visits and lab work. | If side effects occur (e.g., injection-site reactions, headache, nausea, changes in blood pressure or kidney function), the primary investigator or cardiologist/neurologist may reduce dose, space out doses, or stop drug altogether. | None of this monitoring exists when someone orders an “SS-31 research peptide” online and injects at home. That’s why serious complications can go unnoticed until they’re severe. | |
| Both Sexes – Contraindications & High-Risk Situations | Who should avoid unsupervised use | People with unknown or unstable heart disease, arrhythmias, serious kidney or liver disease, pregnancy, breastfeeding, or complex polypharmacy should absolutely not be experimenting with this drug outside formal medical care. | Even in trials, inclusion/exclusion criteria are strict, and many high-risk patients are screened out. | Past severe reactions to peptide therapies, history of unexplained syncope, or uncontrolled blood-pressure issues are reasons to be extra cautious. | For healthy people, the risk/benefit balance strongly favors not using SS-31 off-label; the upside is speculative, but the downside is real and not fully known. | |
| Both Sexes – Storage & Quality | How it’s handled in legit settings | In hospitals and research pharmacies, elamipretide vials are stored refrigerated as directed, protected from light, used within a tight time window after preparation, and discarded if appearance changes or if they pass expiration. | Compounding and handling are done under sterile conditions with quality control. | Documentation includes lot numbers, expiration dates, and clear chain-of-custody, which is completely absent from most internet “research” sources. | If a patient cannot trace their vial back to a known, licensed pharmacy or study site, they should not be injecting it. |
*All numerical ranges and patterns above are broad, trial-style examples, not a personal dosing recipe. Actual mg/kg, route, timing, and duration must be defined by a qualified physician or research protocol based on the specific disease, your bodyweight, organ function, other meds, and local regulations.
⚠️ Warning: This chart is for general educational purposes only and this is not profesional advice or a personal dosing guide. SS-31 (elamipretide) is an investigational mitochondria-targeted peptide that should only be used within formal medical care or approved research. Never start, stop, or change any peptide or drug like SS-31 based on online information or non-medical advice.
